Behera Jiban Kumar, Mishra Pabitra, Jena Anway Kumar, Behera Bhaskar, Bhattacharya Manojit
Department of Zoology, Fakir Mohan University, Vyasa Vihar, Balasore 756020, Odisha, India.
Department of Biosciences and Biotechnology, Fakir Mohan University, Vyasa Vihar, Balasore 756020, Odisha, India.
Sci One Health. 2023 Oct 29;2:100046. doi: 10.1016/j.soh.2023.100046. eCollection 2023.
Emerging diseases are infectious diseases that pose significant threat to human health, causing millions of deaths and disabilities in the upcoming days. Periodic epidemics of new infections and old reinfections increase the global burden of disease prevalence. They can be caused by new pathogens or evolving ones, which change human behavior and environmental factors. Researchers have studied the dynamic connections between microbes, hosts, and the environment, but new infectious diseases like coronavirus disease 2019 (COVID-19), re-emerging diseases, and deliberately disseminated diseases persist despite earlier hopes of elimination. With heavy privatesector investments, Indian pharmacology now provides core Expanded Programme on Immunization vaccines to United Nations International Children's Emergency Fund, producing previously unattainable vaccines for diseases like meningitis, hepatitis B, pneumococcal conjugate, rotavirus, influenza A (H1N1), and COVID-19. India's vaccine sector has emerged, among the oriented leaders of the Bharat Biotech, Serum Institute of India, Panacea Biotech and Biological E. Specifically, the technology transferred from Western countries has benefited the sector, which produces 1.3 billion doses annually. The Serum Institute is the world's largest manufacturer of vaccines, providing measles and diphtheria-tetanus-pertussis vaccines to United Nations. The Serum Institute has developed several vaccines, including Nasovac, MenAfriVac, Pentavac, and an inactivated polio vaccine. India's success in vaccinations can be attributed to attractive investment conditions, government assistance, international alliances, and rising domestic technical talent. Despite its booming economy and technical advances, India's disproportionate share of the world's child mortality rate remains unchanged. However, the growing production and distribution of vaccinations in developing nations has initiated a new era, leading to a worldwide decline in childhood death and disease.
新发疾病是对人类健康构成重大威胁的传染病,在未来可能导致数百万人死亡和残疾。新感染病例的周期性流行以及旧病的再次感染增加了全球疾病流行的负担。它们可能由新出现的病原体或不断演变的病原体引起,这些病原体改变了人类行为和环境因素。研究人员已经研究了微生物、宿主和环境之间的动态联系,但尽管人们曾一度希望消除这些疾病,像2019冠状病毒病(COVID-19)这样的新传染病、再度出现的疾病以及蓄意传播的疾病仍然存在。在私营部门的大量投资下,印度药理学现在为联合国儿童基金会提供核心扩大免疫规划疫苗,生产出了以前无法获得的针对脑膜炎、乙型肝炎、肺炎球菌结合疫苗、轮状病毒、甲型流感(H1N1)和COVID-19等疾病的疫苗。印度的疫苗行业已经崛起,成为了巴拉特生物技术公司、印度血清研究所、泛acea生物技术公司和生物E公司等行业领导者之一。具体而言,从西方国家转让的技术使该行业受益,该行业每年生产13亿剂疫苗。印度血清研究所是世界上最大的疫苗生产商,为联合国提供麻疹和白喉-破伤风-百日咳疫苗。该研究所已经研发出了几种疫苗,包括Nasovac、MenAfriVac、Pentavac和一种灭活脊髓灰质炎疫苗。印度在疫苗接种方面的成功可归因于有吸引力的投资条件、政府援助、国际联盟以及不断增加的国内技术人才。尽管印度经济蓬勃发展且技术进步,但该国在全球儿童死亡率中所占的不成比例份额仍未改变。然而,发展中国家疫苗生产和分发的不断增加开创了一个新时代,导致全球儿童死亡和疾病数量下降。